Anaplastic Pleomorphic Xanthoastrocytoma: Morphological and Molecular Features of Three Cases


Pleomorphic xanthoastrocytoma (PXA) is usually a low grade astrocytic tumor. However, some cases show significant mitotic activity (5 or more mitosis per 10 High Power Field) and/or necrosis. These tumors are described as pleomorphic xanthoastrocytomas with anaplastic features and display increased risk of recurrence. We aimed to evaluate histopathological, immunohistochemical and molecular features of PXAs with anaplastic features, by reporting three primary cases displaying recurrence. Histopathologically we observed rhabdoid-like monomorphic atypical tumoral cells with increased mitotic activity, vascular endothelial proliferation and necrosis. Immunohistochemically, astrocytic and neuronal components displayed different specific staining properties. In 2 cases p53 was immunopositive. We detected BRAF V600E mutation in 2 cases and p16 mutation in one case, by fluorescence in situ hybridization (FISH) method. Anaplastic pleomorphic xanthoastrocytoma (APXA) is a rare tumor. We have presented 3 primary APXA cases displaying all characteristic histopathological features. Two of these cases were immunopositive for p53. Therefore, we think that this marker may not be so useful in differentiating APXA from glioblastoma (GBM). Two of our three cases display BRAF V600E mutation, which is compatible with the literature.

Share and Cite:

Çomunoğlu, N. , Karabağlı, P. , Batur, Ş. and Öz, B. (2015) Anaplastic Pleomorphic Xanthoastrocytoma: Morphological and Molecular Features of Three Cases. Open Journal of Pathology, 5, 117-124. doi: 10.4236/ojpathology.2015.54016.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Giannini, C., Paulus, W., Louis, D.N. and Liberski, P. (2007) Pleomorphic Xanthoastrocytoma. In: Louis, D.N., Ohgaki, H., Wiestler, O.D. and Cavenee, W.K., Eds, World Health Organization Classification of Tumours, WHO Classification of Tumours of the Central Nervous System, IARC Press, Lyon, 22-24.
[2] Burger, P.C. and Scheithauer, B.W. (2007) Pleomorphic Xanthoastrocytoma. In: Burger, P.C. and Scheithauer, B.W., Eds, Tumors of the Central Nervous System, AFIP, Washington DC, 106-113.
[3] Giannini, C., Scheithauer, B.W., Burger, P.C., Brat, D.J., Wollan, P.C., Lach, B. and O’Neill, B.P. (1999) Pleomorphic Xanthoastrocytoma: What Do We Really Know about It? Cancer, 85, 2033-2045.<2033::AID-CNCR22>3.0.CO;2-Z
[4] Marton, E., Feletti, A., Orvieto, E. and Longatti, P. (2007) Malignant Progression in Pleomorphic Xanthoastrocytoma: Personal Experience and Review of the Literature. Journal of the Neurological Sciences, 252, 144-153.
[5] Hirose, T., Ishizawa, K., Sugiyama, K., Kageji, T., Ueki, K. and Kannuki, S. (2008) Pleomorphic Xanthoastrocytoma: A Comparative Pathological Study between Conventional and Anaplastic Types. Histopathology, 52, 183-193.
[6] Sharma, A., Nand Sharma, D., Kumar Julka, P. and Kishor Rath, G. (2011) Pleomorphic Xantho-astrocytoma—A Clinico-Pathological Review. Neurologia i Neurochirurgia Polska, 45, 379-386.
[7] Schmidt, Y., Kleinschmidt-DeMasters, B.K., Aisner, D.L., Lillehei, K.O. and Damek, D. (2013) Anaplastic PXA in Adults: Case Series with Clinicopathologic and Molecular Features. Journal of Neuro-Oncology, 111, 59-69.
[8] Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., Louis, D.N., Korshunov, A., Pfister, S., Hartmann, C., Paulus, W., Reifenberger, G. and von Deimling, A. (2011) Analysis of BRAF V600E Mutation in 1320 Nervous System Tumors Reveals High Mutation Frequencies in Pleomorphic Xanthoastrocytoma, Ganglioglioma and Extra-Cerebellar Pilocytic Astrocytoma. Acta Neuropathologica, 121, 397-405.
[9] Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J.K, Borger, D.R., Batchelor, T.T., Ligon, K.L., Iafrate, A.J., Ligon, A.H., Louis, D.N. and Santagata, S. (2011) BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 29, e17948.
[10] Nasuha, N.A., Daud, A.H., Ghazali, M.M., Yusoff, A.A., Zainuddin, N., Abdullah, J.M., Mutum, S.S., Biswal, B.M., Ariff, A.R., Sulong, S. and Isa, M.N. (2003) Molecular Genetic Analysis of Anaplastic Pleomorphic Xanthoastrocytoma. Asian Journal of Surgery, 26, 120-125.
[11] Kepes, J.J., Rubinstein, L.J. and Eng, L.F. (1979) Pleomorphic Xanthoastrocytoma: A Distinctive Meningocerebral Glioma of Young Subjects with Relatively Favorable Prognosis: A Study of 12 Cases. Cancer, 44, 1839-1852.<1839::AID-CNCR2820440543>3.0.CO;2-0
[12] Gelpi, E., Popovic, M., Preusser, M., Budka, H. and Hainfellner, J. (2005) Pleomorphic Xanthoa-strocytoma with Anaplastic Features Presenting without GFAP Immunoreactivity: Implications for Differential Diagnosis. Neuropathology, 25, 241-246.
[13] Giannini, C., Scheithauer, B.W., Lopes, M.B., Hirose, T., Kros, J.M. and Vanden Berg, S.R. (2002) Immunophenotype of Pleomorphic Xanthoastrocytoma. The American Journal of Surgical Pathology, 26, 479-485.
[14] Hirose, T., Giannini, C. and Scheithauer, B.W. (2001) Ultrastructural Features of Pleomorphic Xanthoastrocytoma: A Comparative Study with Glioblastoma Multiforme. Ultrastructural Pathology, 25, 469-478.
[15] Weldon-Linne, C.M., Victor, T.A., Groothuis, D.R. and Vick, N.A. (1983) Pleomorphic Xanthoa-strocytoma. Ultrastructural and Immunohistochemical Study of a Case with a Rapidly Fatal Outcome Following Surgery. Cancer, 52, 2055-2063.<2055::AID-CNCR2820521115>3.0.CO;2-W
[16] Tsutsumi, S., Abe, Y., Yasumoto, Y. and Ito, M. (2010) Anaplastic Pleomorphic Xanthoastrocytoma with a Component of Anaplastic Astrocytoma Presenting as Skull Base Tumor Followed by Downward Extracranial Extension. Case Report. Neurologia Medico-Chirurgica, 50, 1108-1112.
[17] Vu, T.M., Liubinas, S.V., Gonzales, M. and Drummond, K.J. (2012) Malignant Potential of Pleomorphic Xanthoastrocytoma. Journal of Clinical Neuroscience, 19, 12-20.
[18] Giannini, C., Hebrink, D., Scheithauer, B.W., Dei Tos, A.P. and James, C.D. (2001) Analysis of p53 Mutation and Expression in Pleomorphic Xanthoastrocytoma. Neurogenetics, 3, 159-162.
[19] Perry, A., Giannini, C., Scheithauer, B.W., Rojiani, A.M., Yachnis, A.T., Seo, I.S., Johnson, P.C., Kho, J. and Shapiro, S. (1997) Composite Pleomorphic Xanthoastrocytoma and Ganglioglioma: Report of Four Cases and Review of the Literature. The American Journal of Surgical Pathology, 21, 763-771.
[20] Marko, N.F. and Weil, R.J. (2013) The Molecular Biology of WHO Grade II Gliomas. Neurosurgical Focus, 34, E1.
[21] Marucci, G. and Morandi, L. (2011) Assessment of MGMT Promoter Methylation Status in Pleomorphic Xanthoastrocytoma. Journal of Neuro-Oncology, 105, 397-400.
[22] Gallo, P., Cecchi, P.C., Locatelli, F., Rizzo, P., Ghimenton, C., Gerosa, M. and Pinna, G. (2013) Pleomo-rphic Xanthoastrocytoma: Long-Term Results of Surgical Treatment and Analysis of Prognostic Factors. British Journal of Neurosurgery, 27, 759-764.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.